CVE:ACSTAcasti Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acasti Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.87 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.86Now: C$0.87▼C$0.8950-Day RangeC$0.47MA: C$0.77▼C$0.9652-Week RangeC$0.35Now: C$0.87▼C$4.05Volume27,100 shsAverage Volume188,369 shsMarket CapitalizationC$78.48 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesSocial Media Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Acasti Pharma. Previous Next 2.7 Community Rank Outperform VotesAcasti Pharma has received 132 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcasti Pharma has received 112 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcasti Pharma has received 54.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote “Outperform” if you believe ACST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcasti Pharma does not currently pay a dividend.Dividend GrowthAcasti Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acasti Pharma insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acasti Pharma are expected to grow in the coming year, from C($0.35) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acasti Pharma is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acasti Pharma is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.67 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:ACST Previous SymbolCVE:APO CUSIPN/A CIKN/A Webwww.acastipharma.com Phone+1-450-6864555Debt Debt-to-Equity Ratio52.34 Current Ratio2.07 Quick Ratio1.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.28 per share Price / Cash Flow3.12 Book ValueC($0.07) per share Price / Book-12.61Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares90,209,000Market CapC$78.48 million Next Earnings DateN/A OptionableNot Optionable TSXV:ACST Rates by TradingView Receive ACST News and Ratings via Email Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Acasti Pharma (CVE:ACST) Frequently Asked Questions How has Acasti Pharma's stock been impacted by COVID-19 (Coronavirus)? Acasti Pharma's stock was trading at C$0.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACST shares have increased by 61.1% and is now trading at C$0.87. View which stocks have been most impacted by Coronavirus. Has Acasti Pharma been receiving favorable news coverage? Media headlines about ACST stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acasti Pharma earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutAcasti Pharma. Who are some of Acasti Pharma's key competitors? Some companies that are related to Acasti Pharma include Medicenna Therapeutics (MDNA), ProMetic Life Sciences (PLI), IMV (IMV), Emblem (EMC), Pfenex (PFNX), Exicure (XCUR), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Novacyt (NCYT), Theratechnologies (TH), Exicure (XCUR), Enochian Biosciences (ENOB), Antibe Therapeutics (ATE), IMV (IMV) and Ergomed (ERGO). View all competitors. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Amarin (AMRN), SCYNEXIS (SCYX), Square (SQ), Aurora Cannabis (ACB), ADMA Biologics (ADMA), Blackline (BL), Chewy (CHWY), Crowdstrike (CRWD), Editas Medicine (EDIT) and General Electric (GE). Who are Acasti Pharma's key executives? Acasti Pharma's management team includes the following people: Ms. Janelle D' Alvise, Pres, CEO & DirectorDr. Pierre Lemieux, Co-Founder and Chief Operating & Scientific OfficerMr. Jean-François Boily, VP of Fin.Mr. Brian James Groch, Chief Commercial Officer (Age 52) What is Acasti Pharma's stock symbol? Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST." How do I buy shares of Acasti Pharma? Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Acasti Pharma's stock price today? One share of ACST stock can currently be purchased for approximately C$0.87. How big of a company is Acasti Pharma? Acasti Pharma has a market capitalization of C$78.48 million. What is Acasti Pharma's official website? The official website for Acasti Pharma is www.acastipharma.com. How can I contact Acasti Pharma? Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555. This page was last updated on 5/31/2020 by MarketBeat.com Staff
